# GH Research PLC (GHRS)

> Source: Nexqual · https://nexqual.com/GHRS · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, GH Research PLC (GHRS), nexqual.com/GHRS" · informational, not investment advice.

**Price:** USD 21.5 (+3.81% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 20.71 · day 20.77–22.12 · 52w 12.04–31.44 · market cap $1.48B · NGM

## Key facts
- Analysts: Buy (mean 1.70 on a 1–5 scale) (10 analysts), mean target USD 42.89 (range 38–65).
- Total return with dividends: 1Y +65.2% vs S&P 500 +14.8%; 5Y -15.1% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05 (date not yet confirmed by the company), EPS estimate USD -0.3, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: GHRS paid no cash dividend in the last five years.
- Short interest: 7.47% of float (as of 2026-10-15), 6.4 days to cover.

## Analysts
Consensus Buy (mean 1.70 on a 1–5 scale), 10 analysts; mean target USD 42.89 (low 38, high 65).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | Guggenheim | Target raised | Buy | $34 → $40 |
| 2026-08-07 | Cantor Fitzgerald | Target raised | Overweight | $35 → $40 |
| 2026-08-06 | Needham | Target raised | Buy | $32 → $39 |
| 2026-07-27 | Wells Fargo | Initiated | Overweight | $44 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +65.2% | -15.1% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +65.7% | -3.2% |
| Volatility (annualized) | 69.4% | 69.2% |
| Max drawdown | -41.0% (Aug 2026→Oct 2026) | -79.2% (Nov 2021→Jan 2024) |

## Dividends
GHRS paid no cash dividend in the last five years.

## Short interest
2,010,434 shares sold short, 7.47% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 2,702,630 shares (-25.6%). Days to cover: 6.4 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/GHRS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.30 | $-0.36 | +$0.06 | $0 | 9 |
| Next quarter (ends 2026-12-31) | $-0.35 | $-0.42 | +$0.07 | $0 | 9 |
| Current fiscal year (ends 2026-12-31) | $-1.17 | $-1.40 | +$0.23 | $0 | 9 |
| Next fiscal year (ends 2027-12-31) | $-1.85 | $-2.00 | +$0.15 | $0 | 9 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.23 | −$0.30 | Beat +23.3% | — |
| — | Quarter ended Mar 31, 2026 | −$0.31 | −$0.26 | Miss −19.2% | — |
| — | Quarter ended Dec 31, 2025 | −$0.22 | −$0.27 | Beat +18.5% | — |
| — | Quarter ended Sep 30, 2025 | −$0.23 | −$0.23 | In line | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).